{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Percentage of participants with unacceptable toxicity during the 14-day period post-PVSRIPO treatment","groups":[{"description":"All participants received a single open-label infusion of lerapolturev","id":"OG000","title":"All Participants Treated"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"14 days after treatment with PVSRIPO","title":"Percentage of Participants With Unacceptable Toxicity","type":"PRIMARY","unitOfMeasure":"percentage of participants"}